To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP)
against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged …

The women, men, and transgender people who sell sex globally have disproportionate risks
and burdens of HIV in countries of low, middle, and high income, and in concentrated and …

Background Antiretroviral medications that are used as prophylaxis can prevent acquisition
of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among …

Background Antiretroviral chemoprophylaxis before exposure is a promising approach for
the prevention of human immunodeficiency virus (HIV) acquisition. Methods We randomly …

Abstract In the United States, rates of HIV infection are highest among black men who have
sex with men (BMSM). Pre-exposure prophylaxis (PrEP) is a highly effective form of HIV …

Sex work occurs in many forms and sex workers of all genders have been affected by HIV
epidemics worldwide. The determinants of HIV risk associated with sex work occur at …

While the search for an efficacious HIV-1 vaccine remains elusive, emergence of a new
generation of virus-neutralizing monoclonal antibodies (mAbs) has re-ignited the field of …

Background In VOICE, a multisite HIV pre-exposure prophylaxis (PrEP) trial, plasma drug
levels pointed to widespread product nonuse, despite high adherence estimated by self …

Literature concerning pre-exposure prophylaxis (PrEP) among gay and bisexual identifying
men (GBM) has explored facilitators and barriers to uptake and adherence. Far less reported …

Background: Preexposure prophylaxis (PrEP) is the first biomedical intervention with proven
efficacy to reduce HIV acquisition in men who have sex with men (MSM) and transgender …